Journals / Mersin Üniversitesi Sağlık Bilimleri Dergisi / 2011 / Cilt: 4 - Sayı: 1

Lokal Renin Anjiyotensin Sistemi: Fizyolojik ve Patofizyolojik Etkinliği

Pages
1–6
Publication Date
2011-03-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

With this review, it was aimed to attract more attention to local RAS concept and its effects because of the complexity of the system and more widely use of the drugs affecting it.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Abstract Local Renin-Angiotensin System: Physiologic and Pathophysiologic Effects Renin-angiotensin system (RAS) is one of the most important physiological systems which determines and protects the blood pressure by its effects on fluid and electrolyte balance.
📊
Key Findings & Data:Since the first identification of renin molecule by Tigerstedt and Bergmann in 1898, the renin-angiotensin system (RAS) has been extensively studied.
💡
Conclusion & Impact:With this review, it was aimed to attract more attention to local RAS concept and its effects because of the complexity of the system and more widely use of the drugs affecting it.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Renin-anjiotensin sistemi · anjiotensin II · anjiotensin dönüştürücü enzim 2

Abstract

Abstract Local Renin-Angiotensin System: Physiologic and Pathophysiologic Effects Renin-angiotensin system (RAS) is one of the most important physiological systems which determines and protects the blood pressure by its effects on fluid and electrolyte balance. Since the first identification of renin molecule by Tigerstedt and Bergmann in 1898, the renin-angiotensin system (RAS) has been extensively studied. Angiotensin II, the most dominant effector peptide of the RAS, regulates cellular growth in a wide variety of tissues in (patho)biological states. In addition to the circulating (endocrine) RAS, the existence of RAS in varies tissues and diverse cells has also known. Recent studies have provided evidence of a complete, local RAS within cells, described as an 'intracrine' or intracellular system. The prorenin/ (Pro)renin receptor (PRR)/MAP kinase axis, the ACE2/Ang (1-7)/Mas receptor axis, and the Ang IV/AT II/insulin-regulated aminopeptidase axis also have recently been discovered. From the concept of local RAS, the effect of RAS on tissue and organ levels regardless from its systemic activity is understood. The evidence for physiological and pathophysiological effects of local RAS activities such as cell growth, differantion, proliferation, apoptosis, and formation of reactive oxygen products, tissue inflammation and fibrogenesis is gradually accumulated. Local actors other than the renin (chymase, tonin, i.e.) are thought to be more important in the regulation of local RAS. On the other hand, the members of the circulating RAS contribute to the activity of local RAS in tissues with the exception of brain. A better understanding of the autocrine and paracrine mechanisms involved in the local RASs might direct future organ-specific therapy. With this review, it was aimed to attract more attention to local RAS concept and its effects because of the complexity of the system and more widely use of the drugs affecting it.

Özet

Türkçe Özet: Renin anjiyotensin sistemi (RAS), sıvı ve elektrolit dengesine yaptığı etkilerle kan basıncını belirleyen ve koruyan en önemli fizyolojik sistemlerdendir. İlk kez 1898 yılında Tigerstedt ve Bergmann\'ın renin molekülünü bulmasından bu yana RAS oldukça geniş bir biçimde çalışılmıştır. Anjiyotensin II (ATII), RAS\'ın en fonksiyonel molekülüdür ve birçok biyolojik ve patobiyolojik süreçte etkin rol oynar. Sistemik dolaşımdaki RAS aktivitesinden başka farklı hücre ve dokularda RAS varlığı ve etkinliği de gösterilmiştir. Yakın zamanda yapılan çalışmalar ile, intrakrin ya da “hücre içi” RAS olarak da bilinen lokal RAS\'ın etkinliği gösterilmiştir. Prorenin/Prorenin reseptör/MAP kinaz aksı, anjiyotensin dönüştürücü enzim 2 ADE2/Anjiyotensin (1-7)/Mas reseptör aksı ve anjiyotensin IV/ATII/insulin-regulated aminopeptidaz gibi süreçler yakın zamanda tanımlanmıştır. Lokal RAS varlığının, bulunduğu doku ya da organda; hücre büyümesi, farklılaşması, çoğalması, apoptozisi, reaktif oksijen ürünlerinin oluşumu, doku inflamasyonu ve fibrogenezdeki fizyolojik ve patofizyolojik rollerine dair kanıtlar giderek artmaktadır. Lokal RAS\'ta renin dışındaki faktörlerin (kimaz, tonin vb.) bu sistemin düzenlenmesinde daha baskın olduğu düşünülmektedir. Öte yandan, dolaşımdaki RAS üyeleri de, beyin dışındaki dokularda lokal RAS aktivitesine katkıda bulunmaktadır. Otokrin ve parakrin mekanizmaların daha iyi anlaşılmasıyla organ spesifik tedavide yeni ufukların açılması muhtemeldir. Bu derleme ile sistemin karmaşıklaşmasına ve bu sistemi etkileyen ilaçların yaygın kullanımı nedeniyle lokal RAS kavramı ve etkinliğine dikkat çekilmesi amaçlanmıştır.

🔖

Cite This Article

TURGUTALP, K., KIYKIM, A. A. (2011). Lokal Renin Anjiyotensin Sistemi: Fizyolojik ve Patofizyolojik Etkinliği. Mersin Üniversitesi Sağlık Bilimleri Dergisi, Cilt: 4 - Sayı: 1, 1–6. https://ajindex.com/articles/44147

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (2)

  1. de Gaspare M, Call KJ. Inagami T, Wright JW. Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Phat-maco Rev 2t]titi;52[3}:4lj-T2, Saris JJ. Derkit FH. Lamers JM. Saaena PR. Schalekamp MA, Danser AH. Cardiomyu-cytes bind and activate native prorcnin: role ol' soluble mannose (”J-phosphate receptors. Hyper-tension 2001.37(2):7I0—5. Vaajanen A. Vapaataio H. Local ocular renin-angiotensin systemıa target for glaucoma therapy? Basic Clin Piran-mimi To,-fimi 2t'll 1:109(4):2 I 7-24.
  2. Clermont A. Bursell SE, Feener EP. Role of the angiotensin ll type I receptor in the pathogenesis of diabetic retinopathy: effects of blood pressure control and beyond. J' Hype—neni Suppl 2006;24(I]:S?3—8Ü. Kim HW. Kim.İl. Loc HK. Hur DY. Yurt [H, Kim SD. Enalapril alters expression of key growth factors in experimental diabetic retinopathy. Carr Eve Res 20091340 ”976-87. El Hasnaoui-Saadani R. Piehon A. Marchanl D. Olivier P, Launay T, Quidu P, Beaudry M, Duvallet A, Richalet JP, Fawer F. Cerebral adaptations to chronic anemia in a model ol' eryıhropoielin-tlel'ıcient mice exposed to hypoxia. Am J Physioi Regui fotogr Camp Pity-riot 2009;296[3}1R30 1 -I I. Kim JH, Kim JH, Yu YS, Cho CS. Kim KW. Blockade of angiotensin [I attenuates lııı'EGF-metiiated blood-retinal barrier breakdown in diabetic retinopathy. J Ceren Brand Flaw Match 2009:29[3):62 l -3. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin—Dependent Diabetes Mellitus. twice: [993:35 “909323-31. delie AK. Klein R. Porta M, Orchard T. Fuller J. Parving HH. Bilous R. Chaturyedi N: DIRECT Programme Study Group. DIRECT Programme Study Group. Effect of candesartan on progression and regression ol' retinopathy in type 2 diabetes [DIRECT-Protect 2]: a randomised placebo controlled trial. Lurıı-e-r 2008” 8: 372t964'i): USS-93. Matter M. Zinrnan B. Gardiner R, Suissa S. Sinaiku A. Strand T. Drummond K. Donnelly S. Goodyet P. Gublcr MC. Klein R. Renal and retinal effects of enalapril and losarlan in type I diabetes. N Eng J Med 2009;361t I ):4045I. Ruggenenti P. lliey l. Filipponi M. Tadini S. Porna A. Garteva M. Ene—lordaehe B. Cravedi P. Trevisan R, Bossi A. Remuzzi G. Effect of trarıdolapril on regression of retinopathy in hypertensive patients with type 2 diabetes: a pre-specified analysis of the benedict trial. J Opiıthaimol 2010:201Ü:106384. doi: 10.1155J20l0t’106334. Leung PS. The physiology of a local renin—angiotensin system in the pancreas. J Physio 200T:58'O{l